	US 12,297,502 B2
	Methods and compositions for detecting and diagnosing diseases and conditions
D. Travis Wilson, Newton, MA (US)
Assigned to STEALTH BIOTHERAPEUTICS INC., Needham, MA (US)
Filed by Stealth BioTherapeutics Inc., Needham, MA (US)
Filed on Mar. 30, 2022, as Appl. No. 17/708,909.
Application 16/101,078 is a division of application No. 14/392,293, granted, now 10,047,395, issued on Aug. 14, 2018, previously published as PCT/US2014/043711, filed on Jun. 23, 2014.
Application 17/708,909 is a continuation of application No. 16/101,078, filed on Aug. 10, 2018, granted, now 11,312,993.
Claims priority of provisional application 61/840,760, filed on Jun. 28, 2013.
Claims priority of provisional application 61/839,753, filed on Jun. 26, 2013.
Prior Publication US 2023/0033758 A1, Feb. 2, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/68 (2018.01); C12Q 1/6883 (2018.01); A61K 38/06 (2006.01); G01N 33/92 (2006.01)

CPC C12Q 1/6883 (2013.01) [A61K 38/06 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01); G01N 33/92 (2013.01); G01N 2405/04 (2013.01); G01N 2560/00 (2013.01); G01N 2800/325 (2013.01); G01N 2800/52 (2013.01)]

8 Claims

1. A method for monitoring and treating a subject for heart failure, the method comprising:

(a) detecting levels of monolysocardiolipin acyltransferase (MLCL AT1) or acyl-CoA lysocardiolipin (ALCAT1) mRNA in a biological sample from the subject;

(b) selecting the subject for aromatic-cationic peptide treatment where the level of MLCL AT1 or ALCAT1 mRNA in the biological sample from the subject is elevated about 2.5-fold compared to a normal control sample; and

(c) administering to the subject a therapeutically effective amount of the aromatic-cationic peptide, wherein the aromatic-cationic peptide is D-Arg-2′6′-Dmt-Lys-Phe-NH₂or a pharmaceutically acceptable salt thereof, wherein treatment increases the expression of TAZ1 in the myocardium of the subject.